Blood News and Research

RSS

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).

14 Jun 2010

FRC praises decision of federal Advisory Committee on Blood Safety and Availability

Family Research Council praised today's decision by the federal Advisory Committee on Blood Safety and Availability to reject any change in current blood donation rules. Current policy provides that men who have had sex with men at any time since 1977 are permanently "deferred" from acting as blood donors, because of the high rates of HIV infection in that population. The panel, which offers non-binding advice to the federal Department of Health and Human Services, voted 9-6 on Friday afternoon against recommending any immediate change in the policy.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Researchers identify 2,630 proteins that reside in human spinal fluid

A research team has sharply expanded scientific knowledge of the composition of human spinal fluid. The researchers have identified 2,630 proteins that reside in fluid that is considered "normal," a number nearly three times as great as the total number of proteins previously identified. Another striking finding was that more than half (56%) of the proteins were relatively unique to the spinal fluid and not found in blood.

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

$125M added to plaintiffs' compensation in WTC site operations

The WTC Captive Insurance Company, the City of New York, the contractors the City hired, their subcontractors, and attorneys for over 10,000 plaintiffs alleging injuries from the rescue, recovery and debris removal operations at the World Trade Center site operations after 9/11 today announced amendments to a March 11, 2010 settlement of those claims.

11 Jun 2010

Seminar on pros and cons of robotic surgery

Robotic surgery - is it truly an advance for modern medicine, or just a product of slick consumer advertising campaigns and targeted marketing to physicians?

11 Jun 2010

BMS employees across Canada taking part in third annual Community Action Day

More than 300 employees of Bristol-Myers Squibb Canada will get the day off from their regular work today, but they won't be taking it easy. Instead, they will be joining company retirees and members of their own families in helping out at a variety of community and charitable organizations as part of the company's third annual BMS Community Action Day.

11 Jun 2010

New study to use genetic 'chips' for examining DNA from over 20,000 heart disease patients

New research at the University of Leicester will use the latest genetic techniques to examine DNA from over 20,000 patients with heart disease.

11 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Anoxia-induced suspended animation helps survive hypothermia

How is it that some people who apparently freeze to death, with no heart rate or respiration for extended periods, can be brought back to life with no long-term negative health consequences? New findings from the laboratory of cell biologist Mark B. Roth, Ph.D., of Fred Hutchinson Cancer Research Center, may help explain the mechanics behind this widely documented phenomenon.

11 Jun 2010

FRC supports new blood donation policy

Tomorrow (Friday, June 11), Family Research Council Senior Fellow Peter Sprigg will testify before the Advisory Committee on Blood Safety and Availability (ACBSA) of the Department of Health and Human Services.

11 Jun 2010

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Cancer Research UK scientists have discovered cancer-blocking activity for genes carried on chromosome 21 - an extra copy of which is carried by people with Down's syndrome, reveals research published in Nature.

11 Jun 2010

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Scientists have pinpointed key changes to the telomeres in the cells of leukaemia patients which could play a crucial role in the earliest stages of the disease, according to research published online in the journal Blood.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Blood News and Research

NIH researchers' findings about malaria parasites in bloodstream could lead to development of new drugs

FRC praises decision of federal Advisory Committee on Blood Safety and Availability

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

CNVs increases patients' susceptibility to severe sepsis

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Chiasma successfully completes Phase I clinical study of Octreolin

Researchers identify 2,630 proteins that reside in human spinal fluid

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

$125M added to plaintiffs' compensation in WTC site operations

Seminar on pros and cons of robotic surgery

BMS employees across Canada taking part in third annual Community Action Day

New study to use genetic 'chips' for examining DNA from over 20,000 heart disease patients

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Anoxia-induced suspended animation helps survive hypothermia

FRC supports new blood donation policy

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News